Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices

Xenobiotica

Volumn 42, Issue 8, 2012, Pages 784-790

  Guo, Cheng Xian ^a   Pei, Qi ^a,b   Yin, Ji Ye ^a   Peng, Xiang Dong ^a,b   Zhou, Bo Ting ^a,c   Zhao, Ying Chun ^d   Wu, Lan Xiang ^a,e   Meng, Xiang Guang ^a   Wang, Guo ^a   Li, Qing ^a   Ouyang, Dong Sheng ^a   Liu, Zhao Qian ^a   Zhang, Wei ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Atorvastatin; Ginkgo biloba extract; OATP1B1

Indexed keywords

ATORVASTATIN; CHOLESTEROL; GINKGO BILOBA EXTRACT; LATHOSTEROL; SITOSTEROL;

ADULT; ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; CHOLESTEROL; GINKGO BILOBA; HEPTANOIC ACIDS; HERB-DRUG INTERACTIONS; HUMANS; MALE; PLANT EXTRACTS; PYRROLES; TREATMENT OUTCOME;

GINKGO BILOBA;

EID: 84863651173     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.661100     Document Type: Article

References (51)

1. Amundsen R, Christensen H, Zabihyan B, Asberg A. (2010). Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos 38:1499-1504.
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278.
3. Bays HE, Dujovne CA. (1998). Drug interactions of lipid-altering drugs. Drug Saf 19:355-371. (Pubitemid 28505194)
4. Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA, Schoenberger NE. (2000). Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 81:668-678. (Pubitemid 30257692)
5. Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, Loi CM. (2007). Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos 35:1315-1324. (Pubitemid 47121772)
6. Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, Bruce A, Reynolds RC, Harmatz JS, Avula B, Khan IA, Goldman P. (2006). Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol 46:214-221. (Pubitemid 43149298)
7. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. (2002). Cytochrome P450 phenotypic ratios for predicting herbdrug interactions in humans. Clin Pharmacol Ther 72:276-287.
8. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. (2005). Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 22:525-539. (Pubitemid 41003065)
9. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. (2009). Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatr 80:13-17.
10. He YJ, Zhang W, Chen Y, Guo D, Tu JH, Xu LY, Tan ZR, Chen BL, Li Z, Zhou G, Yu BN, Kirchheiner J, Zhou HH. (2009). Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 405:49-52.
11. Heinemann T, Axtmann G, von Bergmann K. (1993). Comparison of intestinal absorption of cholesterol with different plant sterols in man. Eur J Clin Invest 23:827-831. (Pubitemid 24015625)
12. Hoenig MR, Walker PJ, Gurnsey C, Beadle K, Johnson L. (2010). Markers of cholesterol absorption and synthesis predict the low-density lipoprotein cholesterol response to atorvastatin. J Cardiovasc Pharmacol 56:396-401.
13. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y. (2007). SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 82:541-547. (Pubitemid 47622520)
14. Igel M, Sudhop T, von Bergmann K. (2001). Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 57:357-364. (Pubitemid 33787186)
15. Jacobson TA. (2004). Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94:1140-1146. (Pubitemid 39424216)
16. Jaracz S, Malik S, Nakanishi K. (2004). Isolation of ginkgolides A, B, C, J and bilobalide from G. biloba extracts. Phytochemistry 65:2897-2902. (Pubitemid 40292122)
17. Jemal M, Ouyang Z, Chen BC, Teitz D. (1999). Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 13:1003-1015. (Pubitemid 29257202)
18. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. (2005). Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 59:425-432. (Pubitemid 40523886)
19. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513-522. (Pubitemid 41017600)
20. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. (2008). ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 84:457-461.
21. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. (2009). ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197-203.
22. Lau AJ, Yang G, Rajaraman G, Baucom CC, Chang TK. (2010). Human pregnane X receptor agonism by Ginkgo biloba extract: assessment of the role of individual ginkgolides. J Pharmacol Exp Ther 335:771-780.
23. Lau YY, Huang Y, Frassetto L, Benet LZ. (2007). Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194-204. (Pubitemid 46174816)
24. Lee YJ, Lee MG, Lim LA, Jang SB, Chung JY. (2010). Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 48:36-45.
25. Lei HP, Ji W, Lin J, Chen H, Tan ZR, Hu DL, Liu LJ, Zhou HH. (2009). Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol 68:201-206.
26. Lennern H. (2003). Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141-1160.
27. Li L, Stanton JD, Tolson AH, Luo Y, Wang H. (2009). Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 26:872-882.
28. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R; SEARCH Collaborative Group. (2008). SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359:789-799.
29. Luo Y. (2006). Alzheimer's disease, the nematode Caenorhabditis elegans, and Ginkgo biloba leaf extract. Life Sci 78:2066-2072.
30. Ljohann D, Bjkhem I, Beil UF, von Bergmann K. (1995). Sterol absorption and sterol balance in phytosterolemia evaluated by deuterium-labeled sterols: effect of sitostanol treatment. J Lipid Res 36:1763-1773.
31. Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, Chavin KD. (2003). Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 23:576-581. (Pubitemid 37443189)
32. Neuvonen PJ, Niemi M, Backman JT. (2006). Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-581. (Pubitemid 44908269)
33. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Ljohann D, von Bergmann K, Eichelbaum M, KivistKT. (2005). Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics 15. 303-309. Pharmacogenet Genomics 15:303-309. (Pubitemid 40676551)
34. Niemi M, Pasanen MK, Neuvonen PJ. (2006). SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80:356-366. (Pubitemid 44465886)
35. Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. (2008). Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 38:1240-1251.
36. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. 2007. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82: 726-733. (Pubitemid 350114817)
37. Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M. 2008. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 18:921-926.
38. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. 2006. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873-879. (Pubitemid 44772805)
39. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, Baillie TA. (2002). Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505-512. (Pubitemid 34456970)
40. Reddy P, Ellington D, Zhu Y, Zdrojewski I, Parent SJ, Harmatz JS, Derendorf H, Greenblatt DJ, Browne K Jr. (2011). Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol 72:434-441.
41. Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, Zanger UM. (2010). UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 87:65-73.
42. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. (2008). Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 24:591-599. (Pubitemid 351294409)
43. Shin KH, Kim TE, Kim SE, Lee MG, Song IS, Yoon SH, Cho JY, Jang IJ, Shin SG, Yu KS. (2011). The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol 58:492-499.
44. Uno T, Yasui-Furukori N. (2006). Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol 1:157-161.
45. Von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ. (2004). Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 56:1039-1044. (Pubitemid 39140060)
46. Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D. (2011). Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol 51:378-388.
47. Williams D, Feely J. (2002). Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41:343-370. (Pubitemid 34713089)
48. Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. (2004). The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol 44: 538-542. (Pubitemid 38509723)
49. Yeung EY, Sueyoshi T, Negishi M, Chang TK. (2008). Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos 36:2270-2276.
50. Yoshioka M, Ohnishi N, Koishi T, Obata Y, Nakagawa M, Matsumoto T, Tagagi K, Takara K, Ohkuni T, Yokoyama T, Kuroda K. (2004). Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 27: 2006-2009. (Pubitemid 41701579)
51. Zuo XC, Zhang BK, Jia SJ, Liu SK, Zhou LY, Li J, Zhang J, Dai LL, Chen BM, Yang GP, Yuan H. (2010). Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol 66:503-509.